CTX-8371

N/A

Report date: 2024/04/10 20:04:22

Base Information

Drug NameCTX-8371
Drug Alias NameCTX-8371
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants +[4] 
TargetsProgrammed death-ligand 1Programmed cell death protein 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCompass Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesCompass Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A